Tanja Stocks and colleagues carry out an analysis of six European cohorts and confirm that abnormal glucose metabolism is linked with increased risk of cancer overall and at specific sites

A Tverdal

AJ Sasco

AM Wood

Annekatrin Lukanova

B Lindahl

C La Vecchia

Dorthe Johansen

E Negri

EL Barr

G Berglund

G Whitlock

GD Smith

Göran Hallmans

H Tulinius

Hanno Ulmer

Hans Concin

HD Strickler

Håkan Jonsson

J Danesh

J Gudmundsson

JJ Freiberg

Jonas Manjer

JR Emberson

JS Kasper

K Bjartveit

K Rapp

Kilian Rapp

L Barlow

L Dossus

L Lund Haheim

L Wideroff

LA Johansson

MH Gail

N Aires

Nicholas J. Wareham

O Naess

O Warburg

P Boyle

P Leren

P Stattin

Pär Stattin

R Clarke

R Doll

R Moreno-Sanchez

Randi Selmer

RE Airley

S MacMahon

S Preston-Martin

SH Jee

SH Saydah

SS Coughlin

Steinar Tretli

T Nakagami

T Stocks

Tanja Stocks

Tone Bjørge

W Levine

English

PubMed

Background: Prospective studies have indicated that elevated blood glucose levels may be linked with increased cancer risk, but the strength of the association is unclear. We examined the association between blood glucose and cancer risk in a prospective study of six European cohorts. Methods and Findings: The Metabolic syndrome and Cancer project (Me-Can) includes cohorts from Norway, Austria, and Sweden; the current study included 274,126 men and 275,818 women. Mean age at baseline was 44.8 years and mean follow-up time was 10.4 years. Excluding the first year of follow-up, 18,621 men and 11,664 women were diagnosed with cancer, and 6,973 men and 3,088 women died of cancer. We used Cox regression models to calculate relative risk (RR) for glucose levels, and included adjustment for body mass index (BMI) and smoking status in the analyses. RRs were corrected for regression dilution ratio of glucose. RR (95% confidence interval) per 1 mmol/l increment of glucose for overall incident cancer was 1.05 (1.01–1.10) in men and 1.11 (1.05–1.16) in women, and corresponding RRs for fatal cancer were 1.15 (1.07–1.22) and 1.21 (1.11–1.33), respectively. Significant increases in risk among men were found for incident and fatal cancer of the liver, gallbladder, and respiratory tract, for incident thyroid cancer and multiple myeloma, and for fatal rectal cancer. In women, significant associations were found for incident and fatal cancer of the pancreas, for incident urinary bladder cancer, and for fatal cancer of the uterine corpus, cervix uteri, and stomach. Conclusions: Data from our study indicate that abnormal glucose metabolism, independent of BMI, is associated with an increased risk of cancer overall and at several cancer sites. Our data showed stronger associations among women than among men, and for fatal cancer compared to incident cancer

Stocks, Tanja

Rapp, Kilian

Bjørge, Tone

Manjer, Jonas

Ulmer, Hanno

Selmer, Randi Marie

Lukanova, Annekatrin

Johansen, Dorthe

Concin, Hans

Tretli, Steinar

Hallmans, Göran

Jonsson, Håkan

Stattin, Pär

NORA - Norwegian Open Research Archives

Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts

 Background Prospective studies have indicated that elevated blood glucose levels may increase the risk of cancer, but the strength of the association is unclear. We examined the association between blood glucose and cancer risk in a prospective study of six European cohorts. Methods and Findings The Metabolic syndrome and Cancer project (Me-Can) includes cohorts from Norway, Austria, and Sweden; the current study included 274,126 men and 275,818 women. Mean age at baseline was 44.8 years and mean follow-up time was 10.4 years. Excluding the first year of follow-up, 18,621 men and 11,664 women were diagnosed with cancer, and 6,973 men and 3,088 women died of cancer. We used Cox regression models to calculate relative risk (RR) for glucose levels, and included adjustment for body mass index (BMI) and smoking  status in the analyses. RRs were corrected for regression dilution ratio of glucose. RR (95% confidence interval) per 1 mmol/l increment of glucose for overall incident cancer was 1.05 (1.01-1.10) in men and 1.11 (1.05-1.16) in women, and corresponding RRs for fatal cancer were 1.15 (1.07-1.22) and 1.21 (1.11-1.33), respectively. Significant increases in risk among men were found for incident and fatal cancer of the liver, gallbladder and respiratory tract, for incident thyroid cancer and multiple myeloma, and for fatal rectal cancer. In women, significant associations were found for incident and fatal cancer of the pancreas, for incident urinary bladder cancer, and for fatal cancer of the uterine corpus, cervix uteri, and stomach. Conclusions Data from our study indicate that abnormal glucose metabolism, independently of BMI, is associated with an increased risk of cancer overall and at several cancer sites. Our data showed stronger associations among women than among men, and for fatal cancer compared to incident cancer. 

Bjorge, Tone

Selmer, Randi

Publikationer från Umeå universitet

Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (Me-Can) : analysis of six prospective cohorts.

Digitala Vetenskapliga Arkivet - Academic Archive On-line

Background: Prospective studies have indicated that elevated blood glucose levels may be linked with increased cancer risk, but the strength of the association is unclear. We examined the association between blood glucose and cancer risk in a prospective study of six European cohorts. Methods and Findings: The Metabolic syndrome and Cancer project (Me-Can) includes cohorts from Norway, Austria, and Sweden; the current study included 274,126 men and 275,818 women. Mean age at baseline was 44.8 years and mean follow-up time was 10.4 years. Excluding the first year of follow-up, 18,621 men and 11,664 women were diagnosed with cancer, and 6,973 men and 3,088 women died of cancer. We used Cox regression models to calculate relative risk (RR) for glucose levels, and included adjustment for body mass index (BMI) and smoking status in the analyses. RRs were corrected for regression dilution ratio of glucose. RR (95% confidence interval) per 1 mmol/l increment of glucose for overall incident cancer was 1.05 (1.01-1.10) in men and 1.11 (1.05-1.16) in women, and corresponding RRs for fatal cancer were 1.15 (1.07-1.22) and 1.21 (1.11-1.33), respectively. Significant increases in risk among men were found for incident and fatal cancer of the liver, gallbladder, and respiratory tract, for incident thyroid cancer and multiple myeloma, and for fatal rectal cancer. In women, significant associations were found for incident and fatal cancer of the pancreas, for incident urinary bladder cancer, and for fatal cancer of the uterine corpus, cervix uteri, and stomach. Conclusions: Data from our study indicate that abnormal glucose metabolism, independent of BMI, is associated with an increased risk of cancer overall and at several cancer sites. Our data showed stronger associations among women than among men, and for fatal cancer compared to incident cancer

Hallmans, Goran

Jonsson, Hakan

Stattin, Par

Lund University Publications

Blood Glucose and Risk of Incident and Fatal Cancer in the Metabolic Syndrome and Cancer Project (Me-Can): Analysis of Six Prospective Cohorts

Background: Prospective studies have indicated that elevated blood glucose levels may be linked with increased cancer risk, but the strength of the association is unclear. We examined the association between blood glucose and cancer risk in a prospective study of six European cohorts. Methods and Findings: The Metabolic syndrome and Cancer project (Me-Can) includes cohorts from Norway, Austria, and Sweden; the current study included 274,126 men and 275,818 women. Mean age at baseline was 44.8 years and mean follow-up time was 10.4 years. Excluding the first year of follow-up, 18,621 men and 11,664 women were diagnosed with cancer, and 6,973 men and 3,088 women died of cancer. We used Cox regression models to calculate relative risk (RR) for glucose levels, and included adjustment for body mass index (BMI) and smoking status in the analyses. RRs were corrected for regression dilution ratio of glucose. RR (95% confidence interval) per 1 mmol/l increment of glucose for overall incident cancer was 1.05 (1.01–1.10) in men and 1.11 (1.05–1.16) in women, and corresponding RRs for fatal cancer were 1.15 (1.07–1.22) and 1.21 (1.11–1.33), respectively. Significant increases in risk among men were found for incident and fatal cancer of the liver, gallbladder, and respiratory tract, for incident thyroid cancer and multiple myeloma, and for fatal rectal cancer. In women, significant associations were found for incident and fatal cancer of the pancreas, for incident urinary bladder cancer, and for fatal cancer of the uterine corpus, cervix uteri, and stomach. Conclusions: Data from our study indicate that abnormal glucose metabolism, independent of BMI, is associated with an increased risk of cancer overall and at several cancer sites. Our data showed stronger associations among women than among men, and for fatal cancer compared to incident cancer.publishedVersio

Bergen Open Research Archive (Univ. of Bergen)

Prospective studies have indicated that elevated blood glucose levels may be linked with increased cancer risk, but the strength of the association is unclear. We examined the association between blood glucose and cancer risk in a prospective study of six European cohorts.The Metabolic syndrome and Cancer project (Me-Can) includes cohorts from Norway, Austria, and Sweden; the current study included 274,126 men and 275,818 women. Mean age at baseline was 44.8 years and mean follow-up time was 10.4 years. Excluding the first year of follow-up, 18,621 men and 11,664 women were diagnosed with cancer, and 6,973 men and 3,088 women died of cancer. We used Cox regression models to calculate relative risk (RR) for glucose levels, and included adjustment for body mass index (BMI) and smoking status in the analyses. RRs were corrected for regression dilution ratio of glucose. RR (95% confidence interval) per 1 mmol/l increment of glucose for overall incident cancer was 1.05 (1.01–1.10) in men and 1.11 (1.05–1.16) in women, and corresponding RRs for fatal cancer were 1.15 (1.07–1.22) and 1.21 (1.11–1.33), respectively. Significant increases in risk among men were found for incident and fatal cancer of the liver, gallbladder, and respiratory tract, for incident thyroid cancer and multiple myeloma, and for fatal rectal cancer. In women, significant associations were found for incident and fatal cancer of the pancreas, for incident urinary bladder cancer, and for fatal cancer of the uterine corpus, cervix uteri, and stomach.Data from our study indicate that abnormal glucose metabolism, independent of BMI, is associated with an increased risk of cancer overall and at several cancer sites. Our data showed stronger associations among women than among men, and for fatal cancer compared to incident cancer.Please see later in the article for the Editors' Summar

Stocks Tanja

Rapp Kilian

Bjørge Tone

Manjer Jonas

Ulmer Hanno

Selmer Randi

Lukanova Annekatrin

Johansen Dorthe

Concin Hans

Tretli Steinar

Hallmans Göran

Jonsson Håkan

Stattin Pär

Public Library of Science (PLOS)

Academic Archive On-line (Umeå University, Sweden)

Folkehelseinstituttet

Crossref

A meta-analysis of diabetes mellitus and the risk of prostate cancer.

A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors.

A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones.

Abnormal glucose tolerance and the risk of cancer death in the United States.

Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark.

Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmo Preventive Project.

Cohort profile: cohort of Norway (CONOR).

Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). Int J Epidemiol.

Comparing hospital discharge records with death certificates: can the differences be explained?

Comparing Swedish hospital discharge records with deathcertificates: implications formortalitystatistics.IntJEpidemiol 29:

Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.

Energy metabolism in tumor cells.

European shortlist for causes of death,

Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study.

Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria.

Fasting serum glucose level and cancer risk in Korean men and women.

Food, nutrition, physical activity, and the prevention of cancer: a global perspective.

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin.

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5: e78. doi:10.1371/ journal.pmed.0050078.

Longterm outcome of the Malmo preventive project: mortality and cardiovascular morbidity.

Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years.

Mobasheri A

Nonfasting triglycerides and risk of ischemic stroke in the general population.

Nutrition, metabolic factors and cancer risk.

On the origin of cancer cells.

Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men.

Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry.

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

Prospective study of hyperglycemia and cancer risk.

Random errors in the measurement of 10 cardiovascular risk factors.

Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies.

Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders.

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).

Screening for impaired glucose tolerance. Results from a population-based study in 21,057 individuals.

Serum triglycerides as an independent risk factor for death from coronary heart disease in middle-aged Norwegian men.

Summarizing indices for comparison of cancer incidence data.

The cardiovascular disease study in Norwegian counties. Background and organization.

The cardiovascular disease study in Norwegian counties. Results from first screening.

The completeness of the Swedish Cancer Register – a sample survey for year

The DECODE study group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

The Oslo study. Cardiovascular disease in middle-aged and young Oslo men.

The relation of type 2 diabetes and cancer.

The validity of self-reported leisure time physical activity, and its relationship to serum cholesterol, blood pressure and body mass index. A population based study of 332,182 men and women aged 40–42 years.

Tobacco smoking and cancer: a brief review of recent epidemiological evidence.

Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.

Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.

World Cancer Report

World Health Organisation

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2791167